Dr. Stephen D Ake, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 1610 Commons Cir, Northlake, TX 76226 Phone: 940-725-3400 Fax: 940-278-2282 |
News Archive
One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring a panel of cancer proteins in rare, individual tumor cells that float in the blood.
Shire plc, the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.
Researchers at National Jewish Medical and Research Center are conducting trials to evaluate a method to prevent allergic reactions to food.
Through a process called cell signaling, cells collaborate on necessary functions such as responding to changes in the environment, fighting off threats to the body, or regulating the basic processes that keep the body alive.
Accretive Health, Inc., a leading provider of comprehensive end-to-end healthcare revenue cycle management services, today announced financial results for the quarter ended June 30, 2010.
› Verified 8 days ago